medigraphic.com

2018, Number 2

<< Back Next >>

Cuba y Salud 2018; 13 (2)

Correlation between the presence of pathogenicity factors of Helicobacter pylori and digestive diseases in patients with digestive symptoms. 2012-2016

Duquesne AA, Llanes CR, Feliciano SO, Falcón MR, Figueredo BME, Argudin CM

Language: Spanish
References: 48
Page: 40-47
PDF size: 994.19 Kb.


ABSTRACT

Introduction: the correlation between the factors of pathogenicity of Helicobacter pylori and digestive diseases has not been studied exhaustively in Cuba and there are no reports of this relationship in Primary Health Care.
Objective: to evaluate the correlation between some factors of pathogenicity of Helicobacter pylori and gastroduodenal diseases in Primary Health Care.
Methods: descriptive study in the Polyclinic April 19, the Institute of Tropical Medicine “Pedro Kourí” and the Clinical Surgical Hospital “Manuel Fajardo” from 2012 to 2016 in 60 adults with digestive symptoms, who underwent an endoscopy with three biopsy punch samples for urease test, histopathology and culture of Helicobacter pylori. Venous blood was taken for the evaluation of a commercial Western Blot serological system for the diagnosis of this infection. Pearson’s Chi-square was used to determine the possible relationship between pathogenicity factors and gastroduodenal diseases.
Results: Helicobacter pylori was diagnosed in 38.3% of the patients studied and 30% presented some type of gastric lesion. Peptic ulcer and gastric lesions showed a statistically significant association with the presence of specific proteins of Helicobacter pylori.
Conclusions: the intestinal metaplasia and the totality of the gastric lesions are seen in a statistically significant way in the Helicobacter pylori negative patients. The CagA protein predominates in both groups of patients. There is no statistical association between the specific proteins of Helicobacter pylori and the positive status of the microorganism in the studied patients.


REFERENCES

  1. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011; 20: 299-304.

  2. de Martel C, Ferlay J, Franceschi S. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13: 607-15.

  3. Yoshida T, Kato J, Maekita T, Yamashita S, Enomoto S, Ando T, et al. Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis. Gastric Cancer. 2013; 6:48-50.

  4. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O’Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74e94.

  5. Alonso Soto J, Rodríguez González BL, Moreno Guerra A, Chao González L. Evaluación de la utilidad de diferentes métodos para el diagnóstico de Helicobacter pylori. Revista Cubana de Investigaciones Biomédicas. 2013; 32(1): 102-110.

  6. Ortiz Princz D, Guariglia Oropeza V, Ávila M. Helicobacter pylori cagA and vacA genotypes in Cuban and Venezuelan populations. Memorias do instituto Oswaldo Cruz. 2010; 105(3):331-335.

  7. Torres LE, Bermúdez L, Roblejo Y, Moreno A, Samada M, Cansino J, et al. Desarrollo de un método serológico propio para el diagnóstico de la infección por Helicobacter pylori y su comparación con dos juegos comerciales. Rev CENIC Ciencias Biológicas. 2008; 39:100-106.

  8. Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis 2011;29:459–64.

  9. Verbeke H, Geboes K, van Damme J, Struyf S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cáncer. Biochim Biophys Acta. 2012; 1825:117-129.

  10. Matsuda M, Shiota S, Matsunari O, Watada M, Murakami K, Fujioka T, Yamaoka Y. Prevalence of two homologous genes encoding glycosyltransferases of Helicobacter pylori in the United States and Japan. J Gastroenterol Hepatol. 2011;26(9):1451–6.

  11. Malfertheiner P, Megraud F, O’Morain CA, et al. European Helicobacter Study Group. Management of Helicobacter pylori infectionthe Maastricht IV/ Florence Consensus Report. Gut 2012 May; 61 (5): 646-64.

  12. Kenshi Yao. The endoscopic diagnosis of early gastric cancer Annals of Gastroenterology. 2013; 26(1): 423-432.

  13. Llanes R, Feliciano O, Guzmán D, Gutiérrez O, Valdés L, Llop A, et al. Use of a single biopsy specimen for diagnosing Helicobacter pylori infection by culture and two different PCR methods: Report from Cuba. Tropical Gastroenterology. 2010; 31(2):111–112.

  14. Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol. 2014;20:12781-808.

  15. Cid TP, Fernández MC, Benito Martínez S, Jones NL. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2013; Suppl 1:12–17.

  16. Ministerio de Ciencia, Tecnología y Medio Ambiente. Resolución Nº 38. Lista Oficial de los Agentes Biológicos que afectan al hombre, los animales y las plantas. Gaceta Oficial República de Cuba. 2006; 56: 999-1001.

  17. Ministerio de Ciencia, Tecnología y Medio Ambiente. Resolución Nº 103. Reglamento para el establecimiento de los requisitos y procedimientos de seguridad biológica en las instalaciones en las que se hace uso de agentes biológicos y sus productos, organismos y fragmentos de estos con información genética. La Habana: CITMA; 2002. Disponible en: http://www.medioambiente. cu/legislacione/resoluciones/R-103-02%20CITMA.htm. Citado 16/06/2011.

  18. Sutton P, Lee A. A review article: Helicobacter pylori vaccines – the current status. Aliment Pharmacol Ther. 2010; 14: 1107 – 1108.

  19. Taylor W. Prevention of cancer: a miss. J Ntl Cancer Inst. 2011; 99: 101–103.

  20. Peleteiro B, Bustos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with National coverage. Dig Dis Sci. 2014; 59(8): 1698-709.

  21. Kanzaki H, Uedo N, Ishihara R, Nagai K, Matsui F, Ohta T, et al. Comprehensive investigation of areae gastricae pattern in gastric corpus using magnifying narrow band imaging endoscopy in patients with chronic atrophic fundic gastritis. Helicobacter. 2012;17:224e31.

  22. Sugaro K, Tack J, Kuipers EJ, Graham DY, El Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353-1357.

  23. Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol 2013;10:495–500.

  24. Anuario Estadístico de Salud. 2016. Disponible en: http://www.sld.cu/servicios/estadisticas/. Citado 25/08/2017.

  25. Mulet Pérez AM, Rodríguez Castro Y, Gámez Escalona MM, Rodríguez González L, Rodríguez Dieguez M, Matos Pérez MJ. Gastritis crónica antral por Helicobacter pylori en pacientes con y sin reflujo duodenogástrico. Correo Científico de Holguín. 2014;18(1):65- 78.

  26. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a metaanalysis. Digestion. 2011; 83:253–260.

  27. Goetz M. Endomicroscopy and targeted imaging of gastric neoplasia. Gastrointest Endosc Clin N Am. 2013;23:597-606.

  28. Mulet AM, Gámez MM, Tamayo M, Escobar A, Pozo H, Verdecia AM. Gastritis crónica antral por Helicobacter pylori y enfermedad por reflujo gastroesofágico. Correo Científico Médico. 2012; 16:75-77.

  29. Song J, Zhang J, Wang J, Guo X, Wang J, Liu Y. Meta-analysis: narrow band imaging for diagnosis of gastric intestinal metaplasia. PLoS One. 2014;9:e948-69.

  30. Kikuste I, Stirna D, Liepniece-Karele I, Leja M, Dinis-Ribeiro M. The accuracy of flexible spectral imaging colour enhancement for the diagnosis of gastric intestinal metaplasia: do we still need histology to select individuals at risk for adenocarcinoma? Eur J Gastroenterol Hepatol 2014;26:704e9.

  31. Serrano M, Kikuste I, Dinis-Ribeiro M. Advanced endoscopic imaging for gastric cáncer assessment. New insights with new optics? Best Practice & Research Clinical Gastroenterology. 2014;28:1079e1091.

  32. Piñol F, Paniagua M, Pérez G, Grá B, Cendán A, Borbolla E. Metaplasia intestinal en pacientes con reflujo duodenogástrico y ácidos biliares totales elevados. Revista Cubana de Medicina. 2010; 49:17-32.

  33. Areia M, Carvalho R, Cadime AT, Rocha Gonçalves F, Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter. 2013;18:325e37.

  34. Alaboudy AA, Elbahrawy A, Matsumoto S, Yoshizawa A. Conventional narrowband imaging has good correlation with histopathological severity of Helicobacter pylori gastritis. Dig Dis Sci. 2011;56:1127e30.

  35. Ho B, Marshall BJ. Accurate diagnosis of Helicobacter pylori. Serologic testing. Gastroenterol Clin North Am. 2010; 29:853-62.

  36. Lu W, Wise MJ, Tay CY, Windsor HM, Marshall BJ, Peacock C, Perkins T: Comparative analysis of the full genome of Helicobacter pylori isolate Sahul64 identifies genes of high divergence. J Bacteriol. 2014;196(5):1073–1083.

  37. Dundon WG, De Bernard M, Montecucco C. Virulence factors of Helicobacter pylori. Int J Med Microbiol. 2011; 290: 647-658.

  38. Higashi H, Tsutsumi R, Fujita A, Yamasaki S. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine fosforilation sites. Proc Natl Acad Sci. 2012; 99: 14428-14433.

  39. Toro C, García J, Casado I, Rubio M, Baquero M. Relevancia clínica de las proteínas CagA y VacA y de los factores del huésped en el desarrollo de úlcera péptica en pacientes infectados por Helicobacter pylori. Rev Clin Esp. 2003; 203:430-433.

  40. Song H, Michel A, Nyren O, Ekstrom AM, Pawlita M, Ye W. A cagA-independent cluster of antigens related to the risk of noncardia gastric cáncer: Associations between Helicobacter pylori antibodies and gastric adenocarcinoma explored by multiplex serology. Int J Cancer. 2013; 12: 2942-2950.

  41. Epplein M, Zheng W, Xiang YB, Peek RM, Li H, Correa P, et al. Prospective study of Helicobacter pylori biomarkers for gastric cáncer risk among Chinese men. Cancer Epidemiol Biomarkers Prev. 2012; 21: 2185-2192.

  42. Abasiyanik MF, Sander E, Salihb BA. Helicobacter pylori anti-CagA antibodies: prevalence in symptomatic and asymptomatic subjects in Turkey. Can J Gastroenterol. 2002; 16:527-532.

  43. Michel A, Pawlita M, Boeing H, Gissmann L, Waterboer T. Helicobacter pylori antibody patterns in Germany: a cross sectional population study. Gut Pathogens. 2014; 6:10-16.

  44. Yordanov D, Boyanova L, Markovska R, Gergova G, Mitov I. Significance of Helicobacter pylori vacA intermediate region genotyping-a Bulgarian study. Diagn Microbiol Infect Dis. 2012; 74:253–7.

  45. Mishra S. Is Helicobacter pylori good or bad? Eur J Clin Microbiol Infect Dis. 2013; 32: 301-304.

  46. Pérez Pérez G, Bhat N, Gaensbauer J. Country-specific constancy by ageing cagA proportion of Helicobacter pylori infections. Intern J Cancer. 2007; 72: 453-6.

  47. Franceschi F, Annalisa T, Teresa DR, Giovanna D, Ianiro G, Franco S, Viviana G, Valentina T, Riccardo LL, Antonio G. Role of Helicobacter pylori infection on nutrition and metabolism. World J Gastroenterol. 2014; 20: 12809-12817.

  48. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014; 11: 628-638.




2020     |     www.medigraphic.com